Supernus Pharmaceuticals (SUPN) 10-K2024 FY Annual report

Filed: 25 Feb 25, 4:13pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Avg

New words: accommodate, agonist, AI, Amneal, arose, Banc, blinded, break, breastfeeding, breastmilk, caption, cascade, category, Chevron, cholinergic, Cir, clearing, clinician, CODM, cortex, Council, Daubert, diary, docketed, doctrine, eleven, En, EpiTrack, extra, faith, Fed, format, freedom, Impression, Indemnity, installment, intracellular, KMW, landmark, leachable, LS, MDRP, median, Mexico, Micro, misclassification, misreporting, MJS, monthly, multimodal, neurotrophic, numerically, ONAPGO, ONAPGOTM, overruled, Oxteller, PGIC, pharmacodynamic, pilot, plasticity, pleading, prefrontal, Psychiatric, Psychopharmacology, remission, reproductive, Republic, rescinded, revive, revived, robust, RSUI, split, spoilage, standalone, StarStone, statistically, synapse, tabular, Task, titration, tool, transient, transiently, transporter, Trustworthy, undertaken, visibility, VYALEV, women

Removed: acknowledged, activation, administratively, alia, antidepressant, Apotex, Apydan, assigning, audience, bond, Cadila, Camp, clarify, clarity, closed, compatible, contacted, convenient, conveniently, copied, counsel, deep, deliver, dependency, deployed, Desitin, disclaimed, discontinued, diversity, dosed, Druzbik, Eisai, energy, estimation, eventuality, examine, exploring, extrapyramidal, fiduciary, forward, HC, Hedging, hired, inclusive, inter, interchangeable, invasive, ketamine, Lupin, malware, mg, MN, MSN, Nanomi, NerBloc, Newron, nominal, nonrecourse, Osmotica, pace, parallel, pathology, Patrick, PDUFA, peak, Prinston, Pvt, reorganization, repayment, resubmission, resubmitted, Ricon, RiconPharma, RK, RTF, SAR, serum, situation, stimulation, subcutaneously, Subtopic, suppressed, surgical, synthesize, tablet, terminally, trustee, unspecified, verified, Vertical, virtually, Wilmington, withdrawing, Zenara

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated SUPN transcripts

SUPN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

SUPERNUS PHARMACEUTICALS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. sec. 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Supernus Pharmaceuticals, Inc. (the "Company") on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jack A. Khattar, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



February 25, 2025	By:	s/ JACK A. KHATTAR
		Jack A. Khattar President and Chief Executive Officer